IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Currently amended) A transdermal delivery system (TDS) comprising a backing layer ~~inert to the components of the matrix~~, a self-adhesive matrix containing an amine-functional drug, and a protective foil or sheet to be removed prior to use, ~~characterized in that~~ **wherein** the self-adhesive matrix ~~consists of~~ **comprises** a solid or semisolid semi-permeable polymer
   (1) wherein an amine functional drug in its free base form ~~has been~~ **is** incorporated,
   (2) which ~~is saturated with the amine functional drug and contains said drug as~~ **comprises** a multitude of microreservoirs within the matrix, **said microreservoirs containing the amine functional drug and optionally at least a crystallization inhibitor**,
   (3) which is ~~highly~~ permeable **[[for]] to** the free base of the amine functional drug,
   (4) which is **substantially** impermeable **[[for]] to** the protonated form of the amine functional drug, **and**
   (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix;

   and wherein the backing layer is inert to the components of the matrix.

2. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in that~~ **wherein** the mean diameter of the microreservoirs is in the range of 0.5 to 20 μm.

3. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in~~ **wherein** the amine functional drug ~~having~~ **has** an octanol/water partitioning coefficient (log p) ≥ 2.8 at pH 7.4.

4. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in~~ **wherein** the amine functional drug ~~having~~ **has** a pKa of 7.4 to 8.4.

5. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in that~~ **wherein** the amine functional drug is a dopamine D2 receptor agonist.

6. (Currently amended) The TDS ~~according to~~ **of** claim 5, ~~characterized in that~~ **wherein** the dopamine D2 receptor agonist is an ~~aminotetraline~~ **aminotetralin** compound.

7. (Currently amended) The TDS ~~according to~~ **of** claim 6, ~~characterized in that~~ **wherein** the ~~aminotetraline~~ **aminotetralin** compound is rotigotine.

8. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in that~~ **wherein** the ~~amine-functional~~ **amine functional** drug is an anticholinergic drug.

9. (Currently amended) **The** TDS ~~according to~~ **of** claim 8, ~~characterized in that~~ **wherein** the anticholinergic drug is ~~oxybutynine~~ **oxybutynin**.

10. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in~~ **wherein** the self-adhesive matrix **[[being]] is** free of particles that can absorb salts of the amine functional drug at the TDS/skin interface.

11. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in that~~ **wherein** the polymer matrix comprises a silicone**[[-type]]** pressure sensitive adhesive.

12. (Currently amended) The TDS ~~according to~~ **of** claim 1, ~~characterized in that~~ **wherein** the polymer matrix comprises two or more silicone**[[-type]]** pressure sensitive adhesives as the main adhesive components.

13. (Currently amended) The TDS ~~according to~~ **of** claim 12, wherein the silicone **[[type]]** pressure sensitive adhesive is a blend of a high tack silicone **[[type]]** pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone **[[type]]** pressure sensitive adhesive comprising polysiloxane with a resin.

14. (Currently amended) ~~Method~~ **A method** for treatment of a patient suffering from a disease treatable **[[by]] with** an amine functional drug**, comprising [[by]]** applying the TDS ~~according to~~ **of** claim 1 to the skin of the patient.